Back

Rationale and design of the SHASTA-3 and SHASTA-4 studies: randomized, double-blind, placebo-controlled, phase 3 studies of plozasiran in patients with severe hypertriglyceridemia

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering therapies: new findings Drug therapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Daniel Gaudet

ECOGENE-21 and Community gene medicine center, clinical lipidology unit, Montreal (Canada)

8 More presentations in this session

Presentation thumbnail
Changes in lipid lowering therapy one year after percutaneous coronary intervention: data from the large contemporary ZON-HR registry
Ms D. Peeters (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis
Doctor D. Mutschlechner (Mistelbach, AT)
Abstract Slides Video
Presentation thumbnail
Association of lipid target achievement and cardiovascular outcomes following statin initiation: a population-based cohort study
Doctor J. Udell (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
The impact of discontinuing proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors on clinical outcomes
Doctor H. Tsubata (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events
Doctor I. Dykun (Essen, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering therapies: new findings

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Inhibition of liver ApoC3 by GalNAc-conjugated siRNA RBD5044: first-in-human trial to evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects on atherogenic lipid profiles in heal
thumbnail
Congress Presentation
Icosapent ethyl reduces cardiovascular risk across apolipoprotein b and fasting triglyceride rich lipoprotein levels
thumbnail
Congress Presentation
Phase 1 trial of a monoclonal antibody targeting the angiopoietin-like protein 3/8 complex in patients with mixed hyperlipidaemia

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources